In a report released today, David Saxon from Needham reiterated a Buy rating on Staar Surgical (STAA – Research Report), with a price target of $83.00. The company’s shares closed yesterday at $70.62.
Saxon covers the Healthcare sector, focusing on stocks such as NuVasive, Irhythm Technologies, and Alphatec Holdings. According to TipRanks, Saxon has an average return of -12.9% and a 21.59% success rate on recommended stocks.
Currently, the analyst consensus on Staar Surgical is a Strong Buy with an average price target of $95.57, representing a 35.33% upside. In a report released yesterday, BTIG also maintained a Buy rating on the stock with a $80.00 price target.
See today’s best-performing stocks on TipRanks >>
Based on Staar Surgical’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $81.1 million and a net profit of $13.04 million. In comparison, last year the company earned a revenue of $62.37 million and had a net profit of $8.57 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
STAAR Surgical Co. engages in the development, manufacture, production, marketing, and sale of implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It specializes in refractive and cataract solutions. Its products include intraocular lens and implantable collamer lens. The company was founded in 1982 and is headquartered in Lake Forest, CA.
Read More on STAA:
